The use of fully immersive virtual reality for screening neurodegenerative diseases: A systematic review of behavioral and diagnostic outcomes.
The use of fully immersive virtual reality for screening neurodegenerative diseases: A systematic review of behavioral and diagnostic outcomes.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Canterbury, GB · Author affiliation
School of Computing University of Kent Canterbury UK.Location evidence
Hove, GB · Author affiliation
National Institute of Health and Care Research Applied Research Collaboration Kent Surrey and Sussex, Mill View Site Hove UK.Location evidence
London, GB · Author affiliation
Department of Psychosis Studies Institute of Psychiatry Psychology Neuroscience King's College London, Strand London UK.Location evidence
Kensington, GB · Author affiliation
National Heart & Lung Institute Faculty of Medicine Imperial College London South Kensington Campus London UK.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
Early detection of Alzheimer's disease (AD), Parkinson's disease (PD), and mild cognitive impairment (MCI) is crucial for timely intervention. Traditional cognitive screening tools lack ecological validity and sensitivity. Virtual reality (VR) provides realistic, controlled environments for assessing multidimensional cognition. This systematic review evaluated the diagnostic accuracy, feasibility, and applicability of immersive VR assessments for neurodegenerative screening. We searched PubMed, PsycINFO, and Embase for studies published June 2005 to April 2024. Eligible studies used head-mounted displays in adults with MCI, early AD/PD, or dementia. Ten studies (n = 472) met criteria. Tasks targeted spatial memory, executive function, attention, and navigation. Several reported strong discriminations (area under the curve up to 0.89) and, when combined with machine learning, accuracies of 87% to 100%. Immersive VR shows promise as an ecologically valid, engaging, and scalable screening approach; however, standardization of tasks and outcomes, real-world validation, and robust longitudinal evidence are needed to support clinical adoption.HighlightsThis review systematically describes the application of fully immersive virtual reality (VR) in the early screening of neurodegenerative diseases, with a focus on studies using head-mounted devices to simulate real-life tasks.Task types such as spatial memory, daily living simulations, and executive function assessments have demonstrated high sensitivity and specificity in diagnosing mild cognitive impairment (MCI) and early-stage Alzheimer's disease (AD).Approximately one third of studies combined machine learning techniques to analyze multimodal behavioral data (e.g., path deviations, task duration, and language responses), significantly improving diagnostic accuracy.This study highlights methodological heterogeneity, small sample sizes, and the lack of longitudinal studies as current research limitations, and calls for future standardized, multicenter, and long-term follow-up studies to validate the predictive validity and real-world applicability of VR tools.